ARCH BIOPARTNERS INC/ CA03938C1041 /
| 5/17/2024 9:55:20 PM | Chg. +0.01 | Volume | Bid10:00:03 PM | Ask10:00:03 PM | High | Low |
|---|---|---|---|---|---|---|
| 1.70CAD | +0.59% | 11,500 Turnover: 19,456 |
1.68Bid Size: 400 | 1.73Ask Size: 3,000 | 1.70 | 1.68 |
GlobeNewswire
4/16
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associate...
GlobeNewswire
4/3
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Inju...
GlobeNewswire
4/2
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire
3/18
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ ...
GlobeNewswire
3/15
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated...
GlobeNewswire
3/7
Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Car...
GlobeNewswire
2/27
Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment t...
GlobeNewswire
1/3
Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Tria...
GlobeNewswire
12/21/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
12/13/2023
Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associ...
GlobeNewswire
9/22/2023
Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac...
GlobeNewswire
2/14/2022
Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protoco...
GlobeNewswire
2/3/2022
Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Pe...
GlobeNewswire
1/4/2022
Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to includ...
GlobeNewswire
12/1/2021
Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Tria...
GlobeNewswire
7/14/2021
Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease
GlobeNewswire
6/10/2021
Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediate...
GlobeNewswire
5/4/2021
Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized ...
GlobeNewswire
4/15/2021
Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin...
GlobeNewswire
3/30/2021
Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSAL...
GlobeNewswire
3/24/2021
Arch Biopartners Enters Exclusive License Agreement with the University of Cincinnati for AB569 Topi...
GlobeNewswire
3/16/2021
Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Pep...
